Eli Lilly’s lawsuit against Revive Rx, filed in 2023 in the U.S. District Court for the Southern District of Texas, accuses the Houston compounding pharmacy of mass-producing unapproved copies of Lilly’s tirzepatide drugs Mounjaro and Zepbound and selling them as legitimate compounded medications. After a two-year detour through an appellate ruling on preemption, Judge Lee H. Rosenthal issued a mixed decision in December 2025 that dismissed the Texas claim but let unfair-competition claims under several other states’ laws move forward. The case is now in discovery, with mediation due by July 31, 2026, and a docket call set for November 13, 2026.
What Lilly Says Revive Rx Did
Lilly’s core allegation is that Revive Rx was not filling one-off prescriptions tailored to individual patients, which is what federal compounding law allows, but instead mass-manufacturing a fixed-dose combination of tirzepatide and vitamin B6 for wide distribution. In Lilly’s telling, that crossed the line from pharmacy compounding into unauthorized drug manufacturing, sidestepped FDA safety review, and infringed on the market exclusivity Lilly holds for tirzepatide through at least May 2027.
The complaint also describes what Lilly calls persistent quality problems at the pharmacy: sanitation breakdowns, sterility failures, use of non-pharmaceutical-grade ingredients, and recalls of compounded tirzepatide found to be sub-potent. Lilly points to customer complaints about “watered-down and ineffective” medication and to broader reports of serious injuries and deaths tied to compounded drugs.
The Testosterone Mislabeling Recall
One incident stands out in the record. In April 2024, Revive Rx recalled 751 vials that were labeled as tirzepatide but actually contained testosterone cypionate, a hormone used for entirely different medical purposes. The FDA classified the recall as Class I, its most serious category, reserved for products that could cause serious health consequences or death. The recall covered 34 states.
Patients who thought they were receiving a diabetes or weight-management drug instead received a testosterone product, with risks ranging from blood sugar spikes for diabetic patients to unintended hormonal effects. At least one Houston-area law firm has publicly solicited potential claimants tied to the mislabeling, though the record does not confirm any individual patient suits have been filed.
How Revive Rx Defends Itself
Revive Rx says it is a lawfully licensed 503A pharmacy performing compounding that federal and state law authorize. It points to Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allow pharmacies to compound medications to fill valid prescriptions, particularly when an FDA-approved drug is on the shortage list. Tirzepatide sat on that list from December 2022 until the FDA declared the shortage resolved on December 19, 2024.
The Alliance for Pharmacy Compounding filed an amicus brief backing Revive Rx, arguing that compounding during a shortage is explicitly authorized and that Lilly is trying to reframe legitimate pharmacy work as unauthorized manufacturing.
What the Court Has Ruled
The case stalled for about a year and a half. In December 2023, Judge Rosenthal stayed the lawsuit to wait on the Fifth Circuit’s ruling in Zyla Life Sciences v. Wells Pharma, which asked whether pharmaceutical companies can use state unfair-competition laws against compounders at all, or whether federal drug law preempts those state claims.
On June 5, 2025, the Fifth Circuit ruled that state laws mirroring federal drug-safety requirements are not preempted. Where a state statute incorporates the same standards as the FDCA, the court said, there is “no conflict in terms, and no possibility of such conflict.” That cleared the way for Lilly’s state-law claims to proceed.
Lilly filed an amended complaint, Revive Rx filed a second motion to dismiss in August 2025, and on December 15, 2025, Judge Rosenthal issued a mixed ruling:
- The Texas unfair-competition claim was dismissed with prejudice, because Texas’s own food and drug regulatory scheme forecloses private enforcement through common-law unfair-competition claims.
- The Hawai’i claim was dismissed without prejudice, leaving Lilly the option to refile.
- Claims under Colorado, Connecticut, Tennessee, and Washington law survived.
- Claims under Alaska and North Carolina law survived in part, with the court ordering additional briefing on whether specific statutory exemptions in those states bar the claims.
Discovery is now underway under a full scheduling order. The discovery deadline is July 10, 2026, mediation is due by July 31, 2026, and dispositive motions are due by August 7, 2026. The November 13, 2026 docket call will indicate whether the case is heading to trial.
Parallel FDA Enforcement Against Revive Rx
Separate from Lilly’s suit, the FDA has taken escalating action against Revive Rx’s Houston facility. An inspection in late January and early February 2025 found the pharmacy was preparing sterile drug products under insanitary conditions, including exposing sterile products to substandard air quality, failing to adequately respond to microbial contamination in cleanroom areas, not conducting media fills under worst-case conditions, and lacking validated sterilization cycles for equipment. The FDA issued a warning letter on September 22, 2025, called Revive Rx’s corrective responses deficient, and gave the pharmacy 15 working days to submit a plan or face potential product seizure or an injunction.
A second inspection ran from March 9 to March 27, 2026. The resulting Form 483 documented five categories of violations, four of them flagged as repeat observations. Inspectors again found persistent microbial contamination in areas that should be sterile, inadequate monitoring of personnel, smoke studies performed only under static rather than real-world conditions, sterile products moved through areas with substandard air quality, and equipment that had not been properly sterilized between production runs.
Why This Case Matters Beyond Revive Rx
Revive Rx is one of the earliest and biggest pieces of Lilly’s broader legal campaign against compounders and telehealth companies that built a market around cheaper tirzepatide alternatives. During the shortage, compounded versions sold for as little as $99 a month, compared with Zepbound’s list price above $1,086 a month. As of January 2026, an estimated 1.5 million Americans were using compounded GLP-1 medications.
When the FDA declared the shortage over on December 19, 2024, it gave compounders a wind-down window of 60 days for 503A pharmacies and 90 days for 503B outsourcing facilities. The Outsourcing Facilities Association sued to block the shortage determination, but a federal judge in the Northern District of Texas denied a preliminary injunction on March 5, 2025. That ruling is on appeal to the Fifth Circuit.
Since the shortage ended, the FDA has issued more than 135 warning letters to GLP-1 compounders and telehealth companies, and in February 2026 announced it would use seizure and injunction powers against compounders producing unauthorized GLP-1 products. As of July 2025, the agency had received more than 545 adverse event reports tied to compounded tirzepatide, and about 10 deaths had been potentially linked to compounded GLP-1 drugs.
Lilly has widened its litigation well beyond Revive Rx. In April 2025 it sued two more compounding pharmacies, Strive and Empower, along with telehealth companies Mochi Health, Henry Meds, Fella Health, and Willow Health, accusing the platforms of deceptive advertising and, in some cases, improperly controlling prescribing decisions. Strive has countersued Lilly and Novo Nordisk, alleging the manufacturers are coordinating to suppress competition from compounders.
A Separate Revive Rx Case
One other suit shows up in the record but is not part of Lilly’s case. In April 2025, Revive Rx sued a former associate, Reed Hoelscher, in the Northern District of Texas under the federal Defend Trade Secrets Act. Judge Ed Kinkeade denied the motion to dismiss in March 2026, letting the trade secrets claim proceed.